The root cause of FSHD is the loss of repression at the D4Z4 locus in chromosome 4 leading to aberrant expression of the transcription factor DUX4 in skeletal muscle that activates a transcriptional program resulting in death of skeletal muscle fibers. • The loss of skeletal muscle fibers and their replacement by fat causes weakness, progressive loss of function and disability, affecting face, shoulder and arms, trunk, and legs. • Using optimized myotube culture conditions and FSHD1 and FSHD2 patient-derived myotubes, we identified p38α MAPK as a drug target that plays a critical role in aberrant DUX4 activation. • We selected the small molecule p38α/β MAPK inhibitor losmapimod as a clinical development candidate for treatment of FSHD at its root cause. • Losmapimod was previously studied in 25 clinical trials in over 3,500 subjects across 10 indications but never in FSHD or muscle disease. • Although losmapimod was never filed for approval, it reached phase 3 and showed favorable safety, tolerability, PK, and target engagement including for chronic administration. • Fulcrum acquired an exclusive license for losmapimod, completed a phase 1 trial, and recently started a placebo-controlled trial (named ReDUX4) and open label phase 2 trials in FSHD. • Here we present an overview of the safety and tolerability of losmapimod in previous trials.
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Summary of Data Safety Integration from previous Losmapimod Trials
Conclusion
• There has been extensive investigation of the safety and tolerability of losmapimod in humans. • Data from over 3,500 healthy and diseased subjects generally shows no clinically significant differences in safety and tolerability comparing losmapimod to placebo. • There have been no clinically relevant differences between placebo and losmapimod treatment in ECG abnormalities, rash, immune compromise, liver or renal toxicity. • No safety information exists in human pregnancy. • Assessment of safety, tolerability, ECG, and laboratory abnormalities in FSHD patients is ongoing.
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Summary of Data Safety Integration from COPD Losmapimod Trials
Most Frequent (≥5%) AEs
Across 3 integrated GSK-sponsored repeat dose studies in subjects with COPD, on-treatment SAEs (fatal and non-fatal) were reported by a similar percentage of subjects in the placebo group (21/263, 8%) and the losmapimod group (43/574, 7%). On-treatment SAEs were most frequently reported within the SOC of Respiratory, Thoracic and Mediastinal Disorders.
Summary of Data Safety from Losmapimod Phase 3 Study in Acute Coronary Syndrome (Study PM1116197)
Most Frequent (≥5%) Adverse Events
Most Common (at Least 2%) On-treatment AEs Excluding Adjudicated Cardiovascular Events
Fatal and Non-Fatal SAEs by System Organ Class and Preferred Term Reported by >0.5%
• This is the largest clinical trial ever performed with losmapimod and dosed for 12 weeks. • AEs considered by the investigator to be related to investigational product were reported for 91 (5.2%) subjects in the placebo group and 104 (6.0%) subjects in the losmapimod group. • A total of 125 subjects died (all-cause mortality) through
Week 24 (Day 182). Of these 125 deaths, 57 (3.3%) were in the losmapimod group (47 were adjudicated positively as CV deaths) and 68 (3.9%) were in the placebo group (59 were adjudicated positively as CV deaths).
